Identification and Characterization of a Novel Nanobody Against Human CTGF to Reveal Its Antifibrotic Effect in an in vitro Model of Liver Fibrosis

BACKGROUND: No agents are currently available for the treatment or reversal of liver fibrosis. Novel antifibrotic therapies for chronic liver diseases are thus urgently needed. Connective tissue growth factor (CTGF) has been shown to contributes profoundly to liver fibrogenesis, which makes CTGF as...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Rong, Zhu, Min, Chen, Jiaojiao, Gai, Junwei, Huang, Jing, Zhou, Yingqun, Wan, Yakun, Tu, Chuantao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519214/
https://www.ncbi.nlm.nih.gov/pubmed/37753068
http://dx.doi.org/10.2147/IJN.S428430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519214/
https://www.ncbi.nlm.nih.gov/pubmed/37753068
http://dx.doi.org/10.2147/IJN.S428430

Ejemplares similares